Azitra (AZTR) Net Cash Flow (2022 - 2026)
Azitra (AZTR) posted Net Cash Flow of $8.0 million for Q1 2026, up 1056.39% on a QoQ basis from $690330.0 in Q4 2025, and up 692.2% year-over-year from $1.0 million in Q1 2025.
Azitra (AZTR) Net Cash Flow (2022 - 2026) Analysis & Trends
Azitra's Net Cash Flow history runs 5 years deep, the most recent figure standing at $8.0 million for Q1 2026.
- Quarterly Net Cash Flow rose 692.2% year-over-year to $8.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.9 million (up 3241.45% YoY) and the FY2025 annual result came in at -$2.5 million, down 189.26% from the prior year.
- Net Cash Flow was $8.0 million for Q1 2026 at Azitra, up from $690330.0 in the prior quarter.
- Across five years, Net Cash Flow topped out at $8.0 million in Q1 2026 and bottomed at -$2.7 million in Q4 2024.
- A 5-year average of $421586.3 and a median of -$1.3 million in 2025 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2025 — Net Cash Flow tumbled 211.85% — and 2026, when it soared 692.2%.
- Azitra's Net Cash Flow stood at -$2.4 million in 2022, then retreated by 6.49% to -$2.6 million in 2023, then declined by 3.88% to -$2.7 million in 2024, then soared by 125.52% to $690330.0 in 2025, then jumped by 1056.39% to $8.0 million in 2026.
- Business Quant data shows AZTR's Net Cash Flow at $8.0 million in Q1 2026, $690330.0 in Q4 2025, and $356148.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,769.80 Bn | 1,769.74 Bn | - | - |
| 2 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | -2.44 Mn |
| 3 | BeOne Medicines | 473.64 Bn | 468.85 Bn | 1.35 Bn | 224.46 Mn |
| 4 | Vertex Pharmaceuticals | 123.74 Bn | 116.49 Bn | 2.59 Bn | 457.40 Mn |
| 5 | Regeneron Pharmaceuticals | 71.73 Bn | 62.97 Bn | 3.31 Bn | -152.20 Mn |
| 6 | Belite Bio | 62.10 Bn | 62.10 Bn | - | - |
| 7 | Argenx Se | 54.68 Bn | 49.49 Bn | 1.41 Bn | - |
| 8 | Alnylam Pharmaceuticals | 38.13 Bn | 35.12 Bn | 959.66 Mn | 60.68 Mn |
| 9 | Revolution Medicines | 36.21 Bn | 36.21 Bn | - | 57.19 Mn |
| 10 | Azitra | 2.03 Mn | 2.03 Mn | - | 7.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.98 Mn |
| Mar 31, 2026 | 7.98 Mn |
| Dec 31, 2025 | 690,330.00 |
| Dec 31, 2025 | 690,330.00 |
| Sep 30, 2025 | 356,148.00 |
| Sep 30, 2025 | 356,148.00 |
| Jun 30, 2025 | -2.16 Mn |
| Jun 30, 2025 | -2.16 Mn |
| Mar 31, 2025 | -1.35 Mn |
| Mar 31, 2025 | -1.35 Mn |
| Dec 31, 2024 | -2.71 Mn |
| Dec 31, 2024 | -2.71 Mn |
| Sep 30, 2024 | 6.46 Mn |
| Sep 30, 2024 | 6.46 Mn |
| Jun 30, 2024 | -2.20 Mn |
| Jun 30, 2024 | -2.20 Mn |
| Mar 31, 2024 | 1.21 Mn |
| Mar 31, 2024 | 1.21 Mn |
| Dec 31, 2023 | -2.60 Mn |
| Dec 31, 2023 | -2.60 Mn |